The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection - PubMed (original) (raw)
Clinical Trial
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection
D E Briles et al. Vaccine. 2000.
Abstract
Pneumococcal proteins, alone, in combination with each other, or in combination with capsular polysaccharide-protein conjugates may be useful pneumococcal vaccine components. Four proteins with a potential for use in vaccines are PspA, pneumolysin, PsaA, and PspC. In a mouse model of carriage, PsaA and PspC were the most efficacious vaccine proteins. Of these, PsaA was the best at eliciting protection against carriage. However, a combination of PspA and pneumolysin may elicit stronger immunity to pulmonary infection and possibly sepsis than either protein alone. Recently, a phase one trial of a recombinant family 1 PspA was completed in man. PspA was observed to be safe and immunogenic. Injection of 0.1 ml of immune serum diluted to 1/400 was able to protect mice from fatal infection with S. pneumoniae. Under these conditions, pre-immune serum was not protective. The immune human serum protected mice from infections with pneumococci expressing either of the major PspA families (1 and 2) and both of the pneumococcal capsular types tested: 3 and 6.
Similar articles
- Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
Lu J, Sun T, Wang D, Dong Y, Xu M, Hou H, Kong FT, Liang C, Gu T, Chen P, Sun S, Lv X, Jiang C, Kong W, Wu Y. Lu J, et al. Immunol Invest. 2015;44(5):482-96. doi: 10.3109/08820139.2015.1037956. Immunol Invest. 2015. PMID: 26107747 - Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.
Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS. Briles DE, et al. J Infect Dis. 2000 Dec;182(6):1694-701. doi: 10.1086/317602. Epub 2000 Nov 8. J Infect Dis. 2000. PMID: 11069242 - Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH. Nguyen CT, et al. Vaccine. 2011 Aug 5;29(34):5731-9. doi: 10.1016/j.vaccine.2011.05.095. Epub 2011 Jun 13. Vaccine. 2011. PMID: 21696869 - The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.
Briles DE, Hollingshead SK, Nabors GS, Paton JC, Brooks-Walter A. Briles DE, et al. Vaccine. 2000 Dec 8;19 Suppl 1:S87-95. doi: 10.1016/s0264-410x(00)00285-1. Vaccine. 2000. PMID: 11163470 Review. - Systemic and mucosal protective immunity to pneumococcal surface protein A.
Briles DE, Tart RC, Wu HY, Ralph BA, Russell MW, McDaniel LS. Briles DE, et al. Ann N Y Acad Sci. 1996 Oct 25;797:118-26. doi: 10.1111/j.1749-6632.1996.tb52954.x. Ann N Y Acad Sci. 1996. PMID: 8993356 Review.
Cited by
- Lipidation of pneumococcal proteins enables activation of human antigen-presenting cells and initiation of an adaptive immune response.
Paulikat AD, Schwudke D, Hammerschmidt S, Voß F. Paulikat AD, et al. Front Immunol. 2024 Apr 22;15:1392316. doi: 10.3389/fimmu.2024.1392316. eCollection 2024. Front Immunol. 2024. PMID: 38711516 Free PMC article. - Peptide linker increased the stability of pneumococcal fusion protein vaccine candidate.
Zane L, Kraschowetz S, Trentini MM, Alves VDS, Araujo SC, Goulart C, Leite LCC, Gonçalves VM. Zane L, et al. Front Bioeng Biotechnol. 2023 Jan 26;11:1108300. doi: 10.3389/fbioe.2023.1108300. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 36777254 Free PMC article. - ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification.
Cardoso VM, Paredes SAH, Campani G, Gonçalves VM, Zangirolami TC. Cardoso VM, et al. Appl Microbiol Biotechnol. 2022 Feb;106(3):1011-1029. doi: 10.1007/s00253-022-11758-9. Epub 2022 Jan 13. Appl Microbiol Biotechnol. 2022. PMID: 35024919 Free PMC article. - Control of Streptococcal Infections: Is a Common Vaccine Target Achievable Against Streptococcus agalactiae and Streptococcus pneumoniae.
Bedeley E, Gori A, Yeboah-Manu D, Diallo K. Bedeley E, et al. Front Microbiol. 2021 Apr 23;12:658824. doi: 10.3389/fmicb.2021.658824. eCollection 2021. Front Microbiol. 2021. PMID: 33967998 Free PMC article. Review. - Comparative genomics of invasive Streptococcus pneumoniae CC320/271 serotype 19F/19A before the introduction of pneumococcal vaccine in India.
Varghese R, Neeravi A, Jacob JJ, Vasudevan K, Kumar JL, Subramanian N, Veeraraghavan B. Varghese R, et al. Mol Biol Rep. 2021 Apr;48(4):3265-3276. doi: 10.1007/s11033-021-06353-6. Epub 2021 Apr 19. Mol Biol Rep. 2021. PMID: 33876375
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical